saplin

Compare funds

HDFC Mid Cap vs DSP Midcap

Both are mid cap funds. Over the last 3 years HDFC Mid Cap returned 16.3% a year and DSP Midcap 13.5%, against a category median of 16.4%. HDFC Mid Cap costs 0.73% a year and DSP Midcap 0.83%. On the saplin Score HDFC Mid Cap rates 5.3 (Weak) and DSP Midcap 6.0 (Neutral) within their category. 34.3% of their money is in the same stocks.

Direct plans, growth option. Returns and risk as of 15 Nov 2026; past performance does not tell you future returns. See both side by side with charts.

At a glance

HDFC Mid CapDSP MidcapCategory median
saplin Score (0–10)5.3 Weak6.0 Neutral—
1-year return3.1%2.4%4.9%
3-year return, a year16.3%13.5%16.4%
5-year return, a year17.7%10.9%14.3%
Volatility (standard deviation)16.1%18.5%18.3%
Sharpe ratio0.660.470.62
Beta0.840.960.95
Upside capture919698
Downside capture799990
Expense ratio (Direct)0.73%0.83%0.94%
Fund size₹1,05,346 cr₹20,510 cr₹7,096 cr
Number of holdings786374
Top 10 holdings, share of fund31.7%29.6%27.5%
Portfolio P/E28.132.434.1
Lead managerChirag Setalvad (19 yrs)Vinit Sambre (14 yrs)—
Launched25 Jun 200714 Nov 2006—

Green marks the higher return, Sharpe ratio, upside capture and Score, and the lower volatility, downside capture and cost. That is the direction of each measure, not a recommendation.

Portfolio overlap

HDFC Mid Cap and DSP Midcap have 34.3% of their portfolios in the same stocks (27 holdings in common, portfolios as of 31 Oct 2026). Overlap is the smaller of the two weights in each shared holding, added up: 100% would be identical portfolios.

Biggest shared holdingsHDFC Mid CapDSP Midcap
Coforge3.17%4.92%
IPCA Laboratories3.47%2.94%
The Federal Bank4.31%2.83%
Fortis Healthcare2.42%2.96%
Max Financial Services3.11%2.24%
Mphasis2.06%1.95%
Alkem Laboratories1.94%1.75%
Jindal Steel1.55%2.10%
AU Small Finance Bank3.47%1.51%
Eternal1.47%1.91%

The funds

How the Score works: methodology. Check any set of funds with the overlap checker.

More comparisons

saplin is not registered with SEBI. This page compares published data and is not a recommendation to buy, hold or sell either fund.